Glaucoma News and Research

Latest Glaucoma News and Research

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Low Vision of Michigan introduces new device for RP patients

To commemorate Low Vision Awareness Month this February, Dr. Sheldon Smith, optometrist at Low Vision of Michigan, P.C., is offering free evaluations to patients diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in hopes that they might be candidates for a brand-new device designed to enhance or restore sight.

4 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

Unusual molecule in brain and retina can trigger vision loss

Scientists have identified a double agent in the eye that, once triggered, can morph from neuron protector to neuron killer. The discovery has significant health implications since the neurons killed through this process results in vision loss and blindness.

2 Feb 2010

Health News Digest features Sunridge International's patented 'PNT' procedure

Sunridge International's patented "PNT" procedure was the topic of discussion in one of Health News Digest's recent articles published on January 24, 2010.

27 Jan 2010

Findings provide new insight into factors causing neurodegenerative diseases

Scientists at the Babraham Institute have discovered a novel survival factor whose rapid transport along nerve cells is crucial for keeping them alive. The same factor seems likely to be needed to keep our nerves healthy as we age.

27 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Alcon, the world’s leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

18 Jan 2010

NIH awards IU School of Optometry $2.35M for glaucoma research

An Indiana University School of Optometry researcher's ongoing work to improve testing for and treatment of one of the world's leading causes of blindness will advance with support from a $2.35 million grant from the National Institutes of Health.

18 Jan 2010

Breakthrough discovery could lead to new treatments for a variety of CNS disorders

A breakthrough discovery by scientists at the University of Kentucky could someday lead to new treatments for a variety of diseases of the brain, spinal cord and the eye.

18 Jan 2010

UCL scientists: Simple eye test can help detect and diagnose major neurological diseases

A simple and inexpensive eye test could aid detection and diagnosis of major neurological diseases such as Alzheimer's at an earlier stage than is currently possible, according to new research by UCL scientists.

18 Jan 2010

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

Medical Marijuana Inc applauds the New Jersey State Assembly and Senate for having approved "The New Jersey Compassionate Use Medical Marijuana Act" on Monday, January 11, 2010. A804/S119 removes state-wide penalties for possession of up to two ounces of marijuana when a New Jersey licensed Physician recommends it for one of the qualified medical conditions including Aids, Cancer, Multiple Sclerosis and Crohn's disease among others.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Scientists at deCODE genetics today report the discovery of seven novel and common single-letter variations in the sequence of the human genome (SNPs) that are involved in modulating the electrical impulses that govern the working of the heart.

11 Jan 2010

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

Medical Marijuana launches National Educational Expo at the Los Angeles Convention Center

Medical Marijuana Inc is proud to announce the launch of its first National Educational Expo at the Los Angeles Convention Center, Theatre Room on January 16 & 17, 2010.

5 Jan 2010

Steroids not superior to laser treatments for DME

Researchers led by specialists at the Johns Hopkins Wilmer Eye Institute have found that injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy, a complication of diabetes that frequently leads to blindness.

27 Dec 2009

Beta blockers may increase risk of anemia-induced adverse cardiovascular events

Routinely used to treat patients for heart attack or high blood pressure, beta blockers are known for their role in helping to protect the heart. A new study in the January issue of the journal Anesthesiology looks at the effects of beta blockers on surgical outcomes, revealing that the cardioprotective effects of the medication could be compromised by acute surgical anemia.

23 Dec 2009

Medical Marijuana announces the Nationwide Launch of its Educational Seminar series

Medical Marijuana, Inc. endorsed today the unprecedented act of President Obama signing into federal law the removal of restrictions on the use of medical marijuana in the nation's capitol, which underscores MJNA's foresight in becoming the first US public company to emerge, providing solutions to this revolutionary growth industry.

21 Dec 2009

Glaucoma News and Research

Latest Glaucoma News and Research

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Low Vision of Michigan introduces new device for RP patients

Study shows Cymbalta reduces chronic low back pain

Unusual molecule in brain and retina can trigger vision loss

Health News Digest features Sunridge International's patented 'PNT' procedure

Findings provide new insight into factors causing neurodegenerative diseases

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

NIH awards IU School of Optometry $2.35M for glaucoma research

Breakthrough discovery could lead to new treatments for a variety of CNS disorders

UCL scientists: Simple eye test can help detect and diagnose major neurological diseases

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Medical Marijuana launches National Educational Expo at the Los Angeles Convention Center

Steroids not superior to laser treatments for DME

Beta blockers may increase risk of anemia-induced adverse cardiovascular events

Medical Marijuana announces the Nationwide Launch of its Educational Seminar series

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Glaucoma News and Research

Latest Glaucoma News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in